PMID: 2956028May 1, 1987Paper

Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole

Diabetic Medicine : a Journal of the British Diabetic Association
S SjöbergJ Ostman


Eight patients aged 57-86 years with non-insulin-dependent diabetes mellitus (NIDDM) taking long-term glibenclamide treatment (5-15 mg/day) were given oral trimethoprim-sulphamethoxazole due to an acute bacterial infection. After 4-6 days of combined treatment, the total plasma glibenclamide concentrations were determined every second hour for 12 h, and the area under the curve (AUC) was computed. A second plasma glibenclamide profile was obtained 2-4 weeks after withdrawal of trimethoprim-sulphamethoxazole. The levels of plasma glibenclamide did not differ between the two occasions, nor did the simultaneously determined levels of blood glucose and plasma insulin. It is concluded that there is no consistent pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole in NIDDM patients.


Oct 1, 1994·Journal of Clinical Pharmacology·W A KradjanF C Wood
Jun 1, 1990·British Journal of Clinical Pharmacology·S W CoppackA V Rodgers
Apr 6, 2012·Trends in Pharmacological Sciences·Aleksi TornioJanne T Backman
Mar 1, 1990·DICP : the Annals of Pharmacotherapy·J F Johnson, M E Dobmeier

Related Concepts

Acute Disease
Bacterial Infections
Diabetes Mellitus, Non-Insulin-Dependent
Drug Combinations
Drug Interactions

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

The New England Journal of Medicine
H S Tucker, J I Hirsch
British Journal of Clinical Pharmacology
C G SempleK R Paterson
British Dental Journal
J D Strahan
British Medical Journal
M Nattrass
© 2021 Meta ULC. All rights reserved